Comparing imaging methods for prostate cancer treatment evaluation
Official title: Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) to the Bone: A Whole Body MRI Study
Run by European Institute of Oncology · NCT06321679 · Data updated 2026-11-12
This study is testing whether whole body MRI is better than bone scans and CT scans for checking how well treatments are working in men with advanced prostate cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 40 (estimated) |
| Sponsor | European Institute of Oncology Academic / other |
| Drugs / interventions | denosumab, chemotherapy |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | July 3, 2020 |
| Main results expected | December 31, 2024 |
| Study ends | December 31, 2027 |
| Registry record updated | March 20, 2024 |
| Trial ID | NCT06321679 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with a histological diagnosis of castration-resistant prostate cancer and single or multiple bone metastases.
✕Probably not a fit
Patients with absolute contraindications to WB-MRI, CT, or BS, or those who have undergone radical treatment for metastatic disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to compare the effectiveness of whole body magnetic resonance imaging (WB-MRI) with bone scintigraphy (BS) and computerized tomography (CT) scans in patients with metastatic castration-resistant prostate cancer. Patients will receive various treatment regimens at the discretion of their clinicians, and imaging assessments will be conducted at baseline and every 12 weeks thereafter for up to 192 weeks. The study will also include patient questionnaires to evaluate their perceptions and preferences regarding the imaging modalities used.
Why it matters
Potential benefit: If successful, this study could provide insights into the most effective imaging techniques for monitoring treatment response in prostate cancer patients.
How similar studies have gone: Other studies have shown promising results in using advanced imaging techniques for cancer evaluation, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histological diagnosis of castration-resistant prostate cancer, * Single or multiple bone metastases, * Life expectancy of over 6 months, * No current active malignancy other than prostate cancer, * Provision of written informed consent. Exclusion Criteria: * Absolute contraindication to WB-MRI, CT or BS, * Radical treatment of sole site of metastatic disease (e.g. Cyberknife to solitary metastatic lesion), * Psychological, familial, sociological or geographical conditions that would hamper compliance with the study protocol; such conditions are to be discussed with the patient as part of the informed consent process.
Where it's running
-
IEO Istituto Europeo di Oncologia
Milan, Italy Recruiting
Study contacts
- Principal investigator: Giuseppe Petralia — European Institute of Oncology
- Study coordinator: Giuseppe Petralia, MD
- Email: giuseppe.petralia@ieo.it
- Phone: +39 02 9437 2901
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MRT-2359 plus apalutamide in advanced prostate cancer
This Phase 2 trial tests whether taking MRT-2359 with apalutamide can lower PSA in men with castration-resistant prostate cancer.
-
JANX014 for metastatic castration-resistant prostate cancer
This trial will test whether JANX014 is safe, how your body handles it, and whether it shows signs of benefit in adults with metastatic castration-resistant prostate cancer who have already had anti-androgen therapy and typically a taxane.
-
IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7
This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.
-
Terbium‑161 RAD402 treatment for castration‑resistant prostate cancer
This will test a radioactive antibody called 161Tb‑RAD402 to see if it is safe and can help men with castration‑resistant prostate cancer whose disease has progressed after prior treatments.
-
DCC-2812 in advanced kidney, bladder, and castration-resistant prostate cancers
This trial will test whether the oral drug DCC-2812 is safe and shows early signs of benefit for people with advanced kidney (renal cell), bladder (urothelial), or castration-resistant prostate cancer.
-
GZ17-6.02 treatment for advanced prostate cancer after hormone therapy
This study is testing a new treatment called GZ17-6.02 to see if it can help men with advanced prostate cancer that hasn't responded to hormone therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.